YOLFTbeta
NewcelX Ltd.

NewcelX Ltd.

NCEL · NASDAQ · Healthcare / Biotechnology

2.61USD-0.08 (-2.97%)

Price History

Full chart

Market Stats

Previous Close2.69
Open2.70
Day Range2.55 – 2.70
52-Week Range1.83 – 21.50
Volume12.05K
Market Cap17.02M
P/E (TTM)5.26
Forward P/E0.00
EPS0.56
Dividend Yield0.00%
Beta0.57
50-Day Avg3.40
200-Day Avg3.08

About

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ronen Twito CPA
  • Employees9
  • HeadquartersHohstrasse 1, Kloten, Switzerland, 8302, USA
  • Websitehttps://newcelx.com

Leadership

  • Mr. Ronen Twito CPACEO & Executive Chairman · b. 1975
  • Prof. Michel Revel M.D., Ph.D.Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director · b. 1938
  • Mr. Omri HagaiChief Financial Officer · b. 1986
  • Mr. Alexander C. Zwyer M.B.A.Chief Business Officer & Executive Director · b. 1969
  • Dr. Eric Konofal M.D., Ph.D.Head of Doxa Program · b. 1967
  • Prof. Ariel Revel M.D.Director of Medical Affairs · b. 1961

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----00000
Cost of Revenue----10.05K11.41K11.41K3.32K-
Gross Profit-----10.05K-11.41K-11.41K-3.32K-
Operating Expense----11.85M15.47M11.80M4.38M-
Operating Income-5.77M-3.45K-4.20M-2.30M-11.86M-15.48M-11.81M-4.38M-2.47M
EBITDA-5.77M--430.40K69.56M-11.85M-15.47M-11.80M-3.63M-2.24M
Net Income-6.66M-5.15K-5.45M-2.86M-11.95M-16.50M-12.17M-1.98M-8.30M
R&D4.32M708.461.70M99.58K5.92M8.98M5.91M422.05K1.13M
Interest Expense890.40K1.08K819.71K233.70K68.13K100.87K145.15K150.02K6.01M

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.29M145.63K696.43K1.21M5.76M9.28M1.85M2.23M11.45M
Total Liabilities10.01M8.96M6.87M10.20M5.22M6.00M10.68M826.76K4.20M
Total Equity-7.72M-8.81M-6.17M-8.98M542.39K3.28M-8.83M1.41M7.25M
Cash2.18M6.68K220.27K93.71K5.43M8.95M897.68K1.67M2.20M
Total Debt8.87M7.09M842.13K2.08M--1.63M-355.00K
Net Debt6.68M7.09M621.86K1.99M-5.43M-8.95M736.07K-1.67M-1.85M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.43M-2.73M-190.01K-729.39K-14.94M-13.88M-9.68M-4.27M-2.77M
Investing Cash Flow---217.25K225.64K-39.56K-3.51M--3.92K1.70M
Financing Cash Flow6.73M557.92K407.48K503.52K20.34M17.40M1.63M5.04M2.63M
Capital Expenditure000439.56K640.00K43.92K8.00K
Free Cash Flow-5.43M-2.73M-190.01K-729.39K-14.98M-13.88M-9.68M-4.27M-2.77M
FCF to OCF100.00%100.00%100.00%100.00%100.26%100.00%100.00%100.09%100.29%

Earnings

Report DateFeb 28, 2020Oct 19, 2020May 14, 2021Sep 28, 2021Mar 24, 2022Oct 11, 2022May 5, 2023Oct 18, 2024May 16, 2025Aug 31, 2025Oct 6, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-0.32-0.51-0.24-0.42-1.00-0.54-0.33-1.94-0.99-9.33-1.05
Surprise-----------
Timing-----------

Key Statistics & Ratios

Market Cap17.02M
Enterprise Value16.20M
Trailing P/E5.26
Forward P/E0.00
Price / Sales0.00
Price / Book2.74
EPS0.56
Book Value1.12
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-3.98M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets-49.59%
Shares Outstanding5.78M
Shares Float2.50M
Beta0.57
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
1.34%
Insiders
67.57%
Retail / Other
31.09%

Top Institutional Holders

  • UBS Group AG
    6840.01%
  • Tower Research Capital LLC
    1470.00%
  • CoreCap Advisors, LLC
    30.00%
  • Caitong International Asset Management Co., Limited.
    10.00%

Top Fund Holders

  • SFR Global Wealth Fund
    2500.00%

Stock Splits

  • Oct 31, 20251:10
  • Sep 27, 20241:40